Sort
8,912 grants matching “sars cov 2”
Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip
$732,287John H Connor · Boston University Medical Campus · R01 · FY2023 · HL
Mechanistic modeling of the innate immune responses of the human lung to understand the inter-individual heterogeneity of COVID-19 pneumonia
$731,876Borna Mehrad · University Of Florida · R01 · FY2024 · HL
Mechanisms of anosmia and brain infection in a genetic mouse model of COVID-19
$731,611Sarah E Millar · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · DC
Deep Learning and Subtyping of Post-COVID-19 Lung Progression Phenotypes
$731,422Ching-Long Lin · University Of Iowa · R01 · FY2024 · HL
Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-2
$731,337Kyeong-Ok Chang · Kansas State University · R01 · FY2025 · AI
Evaluating the determinants of the spread of COVID-19 between and within rural communities in Mali, West Africa based on blood-fed mosquitoes
$731,182Tovi Lehmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Long-Term Endothelial Effects of COVID-19 in Obesity
$731,086Jennifer E Ho · Beth Israel Deaconess Medical Center · R01 · FY2022 · HL
Inborn errors of immunity in patients with life-threatening COVID-19
$730,959Jean-Laurent Casanova · Rockefeller University · R01 · FY2024 · AI
Small Molecule Protease Inhibitors against MERS-CoV
$730,761Kyeong-Ok Chang · Kansas State University · R01 · FY2021 · AI
Human coronavirus infection of the nasal epithelium
$730,697Susan R. Weiss · University Of Pennsylvania · R01 · FY2024 · AI
Human coronavirus infection of the nasal epithelium
$730,697Susan R. Weiss · University Of Pennsylvania · R01 · FY2025 · AI
iPSC-Derived Vascularized Human Lung Organoids and Interaction Between Lung Endothelial Cells and Alveolar Epithelial Cells
$730,601Asrar B. Malik · University Of Illinois At Chicago · R01 · FY2022 · HL
iPSC-Derived Vascularized Human Lung Organoids and Interaction Between Lung Endothelial Cells and Alveolar Epithelial Cells
$730,601Jalees Rehman · University Of Illinois At Chicago · R01 · FY2025 · HL
iPSC-Derived Vascularized Human Lung Organoids and Interaction Between Lung Endothelial Cells and Alveolar Epithelial Cells
$730,601Asrar B. Malik · University Of Illinois At Chicago · R01 · FY2023 · HL
Development of dual inhibitors targeting the viral main protease and the host cathepsin L as SARS-CoV-2 antivirals
$730,106Jun Wang · Rutgers Biomedical And Health Sciences · R01 · FY2023 · AI
SARS-CoV-2 Genomic Surveillance in North Louisiana
$730,000Christopher G Kevil · Louisiana State Univ Hsc Shreveport · P20 · FY2022 · GM
SARS-CoV-2 Genomic Surveillance in North Louisiana
$730,000Christopher G Kevil · Louisiana State Univ Hsc Shreveport · P20 · FY2021 · GM
Mechanisms of BNT162b2 Vaccine Immunogenicity in Systemic Lupus Erythematosus or Scleroderma
$729,999Paul Joseph Utz · Stanford University · R01 · FY2025 · AI
Sex specific immune response to SARS-CoV-2 leads to chronic neurologic symptoms
$729,940Louise Deborah McCullough · University Of Texas Hlth Sci Ctr Houston · R01 · FY2022 · MH
Marshallese: Alternate Surveillance for COVID-19 in a Unique Population
$729,868Ka'imi Alohilani Sinclair · Washington State University · R01 · FY2022 · MD
The Impact of SARS-CoV-2 Immune Dysregulation on Antifungal Immunity
$729,390Sixto Manuel Leal · University Of Alabama At Birmingham · R01 · FY2025 · AI
Trusted Messengers: Supporting Physicians in Promoting COVID-19 Vaccination
$728,956Kimberly Fisher · Univ Of Massachusetts Med Sch Worcester · R01 · FY2022 · MD
Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2
$728,745Samarjit Das · Johns Hopkins University · U18 · FY2022 · TR
Small Molecule Protease Inhibitors against MERS-CoV
$728,584Kyeong-Ok Chang · Kansas State University · R01 · FY2022 · AI
Development of Population Level Serotyping Technology and Antibody Profiling for Infectious Pathogens with focus on Influenza and SARS-CoV-2
$728,518Eric Okerberg · Encodia, Inc. · R44 · FY2020 · CA